Which has higher valuation and earnings, BIIB or AMGN?

Amgen has higher revenue and earnings than Biogen. Amgen is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biogen $9.89B 3.32 $1.29B $5.65 39.32 Amgen $36.75B 6.08 $7.71B $16.09 25.67

Is BIIB or AMGN more profitable?

Amgen has a net margin of 22.95% compared to Biogen's net margin of 8.32%. Amgen's return on equity of 124.14% beat Biogen's return on equity. Company Net Margins Return on Equity Return on Assets Biogen 8.32% 11.18% 6.88% Amgen 22.95% 124.14% 13.18%

Does the media prefer BIIB or AMGN?

In the previous week, Amgen had 3 more articles in the media than Biogen. MarketBeat recorded 22 mentions for Amgen and 19 mentions for Biogen. Biogen's average media sentiment score of 0.85 beat Amgen's score of 0.67 indicating that Biogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 8 Very Positive mention(s) 5 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Amgen 11 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, GILD or BIIB?

Gilead Sciences has higher revenue and earnings than Biogen. Gilead Sciences is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gilead Sciences $29.44B 6.18 $8.51B -$2.67 N/A Biogen $9.89B 3.32 $1.29B $5.65 39.32

Is GILD or BIIB more profitable?

Biogen has a net margin of 8.32% compared to Gilead Sciences' net margin of -10.64%. Biogen's return on equity of 11.18% beat Gilead Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Gilead Sciences -10.64% -2.11% -0.75% Biogen 8.32% 11.18% 6.88%

Does the media prefer GILD or BIIB?

In the previous week, Gilead Sciences had 7 more articles in the media than Biogen. MarketBeat recorded 26 mentions for Gilead Sciences and 19 mentions for Biogen. Biogen's average media sentiment score of 0.85 beat Gilead Sciences' score of 0.51 indicating that Biogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gilead Sciences 10 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Biogen 8 Very Positive mention(s) 5 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media favor BIIB or IONS?

In the previous week, Biogen had 15 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 19 mentions for Biogen and 4 mentions for Ionis Pharmaceuticals. Biogen's average media sentiment score of 0.85 beat Ionis Pharmaceuticals' score of -0.34 indicating that Biogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 8 Very Positive mention(s) 5 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Ionis Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, BIIB or MRNA?

Biogen has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biogen $9.89B 3.32 $1.29B $5.65 39.32 Moderna $1.94B 40.35 -$2.82B -$7.99 N/A

Is BIIB or MRNA more profitable?

Biogen has a net margin of 8.32% compared to Moderna's net margin of -141.43%. Biogen's return on equity of 11.18% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets Biogen 8.32% 11.18% 6.88% Moderna -141.43% -28.30% -19.39%

Does the media prefer BIIB or MRNA?

In the previous week, Moderna had 27 more articles in the media than Biogen. MarketBeat recorded 46 mentions for Moderna and 19 mentions for Biogen. Biogen's average media sentiment score of 0.85 beat Moderna's score of 0.13 indicating that Biogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 8 Very Positive mention(s) 5 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Moderna 10 Very Positive mention(s) 10 Positive mention(s) 16 Neutral mention(s) 7 Negative mention(s) 2 Very Negative mention(s) Neutral

Biogen (BIIB) Competitors

$216.73 -5.42 (-2.44%)

As of 03:25 PM Eastern

Compare

BIIB vs. AMGN, DNLI, GILD, IONS, and MRNA

Should you buy Biogen stock or one of its competitors? Biogen's main competitors and comparable companies include Amgen (AMGN), Denali Therapeutics (DNLI), Gilead Sciences (GILD), Ionis Pharmaceuticals (IONS), and Moderna (MRNA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Biogen compare to Amgen?

Biogen (NASDAQ:BIIB) and Amgen (NASDAQ:AMGN) are both large-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation.

In the previous week, Amgen had 3 more articles in the media than Biogen. MarketBeat recorded 22 mentions for Amgen and 19 mentions for Biogen. Biogen's average media sentiment score of 0.85 beat Amgen's score of 0.67 indicating that Biogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	8 Very Positive mention(s)	5 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Amgen	11 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

87.9% of Biogen shares are held by institutional investors. Comparatively, 76.5% of Amgen shares are held by institutional investors. 0.3% of Biogen shares are held by company insiders. Comparatively, 0.9% of Amgen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Biogen has a beta of 0.09, suggesting that its stock price is 91% less volatile than the broader market. Comparatively, Amgen has a beta of 0.41, suggesting that its stock price is 59% less volatile than the broader market.

Biogen presently has a consensus price target of $230.14, indicating a potential upside of 3.60%. Amgen has a consensus price target of $385.79, indicating a potential downside of 6.61%. Given Biogen's stronger consensus rating and higher probable upside, research analysts clearly believe Biogen is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	1 Sell rating(s)	13 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.56
Amgen	3 Sell rating(s)	16 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.30

Amgen has higher revenue and earnings than Biogen. Amgen is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.89B	3.32	$1.29B	$5.65	39.32
Amgen	$36.75B	6.08	$7.71B	$16.09	25.67

Amgen has a net margin of 22.95% compared to Biogen's net margin of 8.32%. Amgen's return on equity of 124.14% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	8.32%	11.18%	6.88%
Amgen	22.95%	124.14%	13.18%

Summary

Amgen beats Biogen on 10 of the 16 factors compared between the two stocks.

How does Biogen compare to Denali Therapeutics?

Biogen (NASDAQ:BIIB) and Denali Therapeutics (NASDAQ:DNLI) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

Biogen has a beta of 0.09, meaning that its stock price is 91% less volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 1.02, meaning that its stock price is 2% more volatile than the broader market.

Biogen has a net margin of 8.32% compared to Denali Therapeutics' net margin of 0.00%. Biogen's return on equity of 11.18% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	8.32%	11.18%	6.88%
Denali Therapeutics	N/A	-55.27%	-44.24%

In the previous week, Biogen had 19 more articles in the media than Denali Therapeutics. MarketBeat recorded 19 mentions for Biogen and 0 mentions for Denali Therapeutics. Biogen's average media sentiment score of 0.85 beat Denali Therapeutics' score of 0.00 indicating that Biogen is being referred to more favorably in the media.

Company	Overall Sentiment
Biogen	Positive
Denali Therapeutics	Neutral

Biogen presently has a consensus target price of $230.14, suggesting a potential upside of 3.60%. Denali Therapeutics has a consensus target price of $35.85, suggesting a potential upside of 87.09%. Given Denali Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Denali Therapeutics is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	1 Sell rating(s)	13 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.56
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

Biogen has higher revenue and earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.89B	3.32	$1.29B	$5.65	39.32
Denali Therapeutics	$330.53M	9.27	-$512.54M	-$2.84	N/A

87.9% of Biogen shares are owned by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are owned by institutional investors. 0.3% of Biogen shares are owned by company insiders. Comparatively, 9.7% of Denali Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Biogen beats Denali Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Biogen compare to Gilead Sciences?

Gilead Sciences (NASDAQ:GILD) and Biogen (NASDAQ:BIIB) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends, media sentiment and earnings.

Gilead Sciences has a beta of 0.31, indicating that its stock price is 69% less volatile than the broader market. Comparatively, Biogen has a beta of 0.09, indicating that its stock price is 91% less volatile than the broader market.

Gilead Sciences has higher revenue and earnings than Biogen. Gilead Sciences is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gilead Sciences	$29.44B	6.18	$8.51B	-$2.67	N/A
Biogen	$9.89B	3.32	$1.29B	$5.65	39.32

In the previous week, Gilead Sciences had 7 more articles in the media than Biogen. MarketBeat recorded 26 mentions for Gilead Sciences and 19 mentions for Biogen. Biogen's average media sentiment score of 0.85 beat Gilead Sciences' score of 0.51 indicating that Biogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gilead Sciences	10 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Biogen	8 Very Positive mention(s)	5 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Biogen has a net margin of 8.32% compared to Gilead Sciences' net margin of -10.64%. Biogen's return on equity of 11.18% beat Gilead Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gilead Sciences	-10.64%	-2.11%	-0.75%
Biogen	8.32%	11.18%	6.88%

83.7% of Gilead Sciences shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 0.3% of Gilead Sciences shares are owned by insiders. Comparatively, 0.3% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Gilead Sciences presently has a consensus price target of $159.15, suggesting a potential upside of 8.37%. Biogen has a consensus price target of $230.14, suggesting a potential upside of 3.60%. Given Gilead Sciences' stronger consensus rating and higher probable upside, research analysts plainly believe Gilead Sciences is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gilead Sciences	0 Sell rating(s)	6 Hold rating(s)	23 Buy rating(s)	0 Strong Buy rating(s)	2.79
Biogen	1 Sell rating(s)	13 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.56

Summary

Gilead Sciences beats Biogen on 9 of the 17 factors compared between the two stocks.

How does Biogen compare to Ionis Pharmaceuticals?

Biogen (NASDAQ:BIIB) and Ionis Pharmaceuticals (NASDAQ:IONS) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.

In the previous week, Biogen had 15 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 19 mentions for Biogen and 4 mentions for Ionis Pharmaceuticals. Biogen's average media sentiment score of 0.85 beat Ionis Pharmaceuticals' score of -0.34 indicating that Biogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	8 Very Positive mention(s)	5 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Ionis Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Biogen has a net margin of 8.32% compared to Ionis Pharmaceuticals' net margin of -64.76%. Biogen's return on equity of 11.18% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	8.32%	11.18%	6.88%
Ionis Pharmaceuticals	-64.76%	-111.08%	-17.41%

Biogen has a beta of 0.09, indicating that its stock price is 91% less volatile than the broader market. Comparatively, Ionis Pharmaceuticals has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market.

Biogen currently has a consensus price target of $230.14, suggesting a potential upside of 3.60%. Ionis Pharmaceuticals has a consensus price target of $89.20, suggesting a potential upside of 101.99%. Given Ionis Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Ionis Pharmaceuticals is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	1 Sell rating(s)	13 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.56
Ionis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.73

87.9% of Biogen shares are held by institutional investors. Comparatively, 93.9% of Ionis Pharmaceuticals shares are held by institutional investors. 0.3% of Biogen shares are held by insiders. Comparatively, 1.8% of Ionis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Biogen has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.89B	3.32	$1.29B	$5.65	39.32
Ionis Pharmaceuticals	$944M	7.77	-$381.39M	-$3.46	N/A

Summary

Biogen beats Ionis Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Biogen compare to Moderna?

Biogen (NASDAQ:BIIB) and Moderna (NASDAQ:MRNA) are both large-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings.

87.9% of Biogen shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 0.3% of Biogen shares are owned by company insiders. Comparatively, 10.8% of Moderna shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Biogen has a beta of 0.09, meaning that its share price is 91% less volatile than the broader market. Comparatively, Moderna has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market.

In the previous week, Moderna had 27 more articles in the media than Biogen. MarketBeat recorded 46 mentions for Moderna and 19 mentions for Biogen. Biogen's average media sentiment score of 0.85 beat Moderna's score of 0.13 indicating that Biogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	8 Very Positive mention(s)	5 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Moderna	10 Very Positive mention(s)	10 Positive mention(s)	16 Neutral mention(s)	7 Negative mention(s)	2 Very Negative mention(s)	Neutral

Biogen presently has a consensus price target of $230.14, indicating a potential upside of 3.60%. Moderna has a consensus price target of $78.17, indicating a potential downside of 60.22%. Given Biogen's stronger consensus rating and higher possible upside, analysts plainly believe Biogen is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	1 Sell rating(s)	13 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.56
Moderna	5 Sell rating(s)	13 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.08

Biogen has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.89B	3.32	$1.29B	$5.65	39.32
Moderna	$1.94B	40.35	-$2.82B	-$7.99	N/A

Biogen has a net margin of 8.32% compared to Moderna's net margin of -141.43%. Biogen's return on equity of 11.18% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	8.32%	11.18%	6.88%
Moderna	-141.43%	-28.30%	-19.39%

Summary

Biogen beats Moderna on 13 of the 17 factors compared between the two stocks.

Get Biogen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIIB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BIIB vs. The Competition

Export

Metric	Biogen	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$32.11B	$3.82B	$7.12B	$13.20B
Dividend Yield	N/A	3.66%	2.53%	16.47%
P/E Ratio	38.46	13.59	275.61	25.91
Price / Sales	3.25	1,174.20	566.19	83.48
Price / Cash	9.85	118.37	77.41	52.81
Price / Book	1.75	16.07	10.78	6.25
Net Income	$1.29B	-$22.69M	$3.50B	$382.13M
7 Day Performance	-2.36%	-3.60%	-2.15%	-1.55%
1 Month Performance	2.38%	-12.81%	-7.66%	-5.78%
1 Year Performance	44.11%	9.17%	3.16%	-1.67%

Biogen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BIIB Biogen	3.3936 of 5 stars	$217.56 -2.1%	$230.00 +5.7%	+45.9%	$32.11B	$9.89B	38.46	7,500	Analyst Forecast
AMGN Amgen	3.5481 of 5 stars	$418.13 +0.8%	$385.25 -7.9%	+39.8%	$226.05B	$38.10B	25.99	31,500	Trending News Analyst Forecast
DNLI Denali Therapeutics	2.0327 of 5 stars	$20.98 +2.9%	$35.85 +70.9%	+28.6%	$3.35B	$330.53M	N/A	507
GILD Gilead Sciences	4.2795 of 5 stars	$152.21 +0.8%	$158.78 +4.3%	+25.7%	$188.73B	$30.46B	N/A	17,000	Trending News Analyst Forecast Analyst Revision
IONS Ionis Pharmaceuticals	3.4394 of 5 stars	$45.57 +2.4%	$89.20 +95.7%	-35.9%	$7.57B	$874.09M	N/A	1,402

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BIIB) was last updated on 10/8/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biogen (BIIB) Competitors

BIIB vs. AMGN, DNLI, GILD, IONS, and MRNA

How does Biogen compare to Amgen?

Summary

How does Biogen compare to Denali Therapeutics?

Summary

How does Biogen compare to Gilead Sciences?

Summary

How does Biogen compare to Ionis Pharmaceuticals?

Summary

How does Biogen compare to Moderna?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIIB vs. The Competition

Biogen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biogen (BIIB) Competitors

BIIB vs. AMGN, DNLI, GILD, IONS, and MRNA

How does Biogen compare to Amgen?

Does the media prefer BIIB or AMGN?

Do institutionals and insiders have more ownership in BIIB or AMGN?

Which has more risk and volatility, BIIB or AMGN?

Do analysts prefer BIIB or AMGN?

Which has higher valuation and earnings, BIIB or AMGN?

Is BIIB or AMGN more profitable?

Summary

How does Biogen compare to Denali Therapeutics?

Which has more risk and volatility, BIIB or DNLI?

Is BIIB or DNLI more profitable?

Does the media refer more to BIIB or DNLI?

Do analysts rate BIIB or DNLI?

Which has preferable valuation & earnings, BIIB or DNLI?

Do insiders & institutionals hold more shares of BIIB or DNLI?

Summary

How does Biogen compare to Gilead Sciences?

Which has more risk & volatility, GILD or BIIB?

Which has preferable valuation & earnings, GILD or BIIB?

Does the media prefer GILD or BIIB?

Is GILD or BIIB more profitable?

Do insiders and institutionals hold more shares of GILD or BIIB?

Do analysts recommend GILD or BIIB?

Summary

How does Biogen compare to Ionis Pharmaceuticals?

Does the media favor BIIB or IONS?

Is BIIB or IONS more profitable?

Which has more risk & volatility, BIIB or IONS?

Do analysts rate BIIB or IONS?

Do institutionals and insiders believe in BIIB or IONS?

Which has higher earnings and valuation, BIIB or IONS?

Summary

How does Biogen compare to Moderna?

Do insiders & institutionals believe in BIIB or MRNA?

Which has more volatility & risk, BIIB or MRNA?

Does the media prefer BIIB or MRNA?

Do analysts prefer BIIB or MRNA?

Which has higher valuation and earnings, BIIB or MRNA?

Is BIIB or MRNA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIIB vs. The Competition

Biogen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools